Absence of mutations in the p53 tumor suppressor gene in non-invasive cushing adenomas

Medicina

Volumn 59, Issue 5 I, 1999, Pages 459-462

  Copelli, Silvia B ^a   Coll, Mariano A Loza ^b   Bruno, Oscar D ^b  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b NONE

Author keywords

Corticotropinoma; P53 gene; PCR SSCP

Indexed keywords

ADENOMA; ARTICLE; CUSHING SYNDROME; EXON; GENETIC MARKER; GENETICS; HUMAN; MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADENOMA; CUSHING SYNDROME; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXONS; GENES, P53; GENETIC MARKERS; HUMANS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0033254554     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Carey RM, Varma SK, Drake Jr CR, et al. Ectopic secretion of corticotroping releasing factor as a cause of Cushing's syndrome. N Engl J Med 1984; 311: 13-20.
2. Alexander JM, Billed BMK, Bikkal H, et al. Clinically nonfunctioning pituitary tumor are monoclonal in origin. J Clin Invest 1990; 86: 336-40.
3. Shimon I, Melmed S. Genetic basis of endocrine disease. Pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997; 82: 1675-81.
4. Lees E. Cyclin dependent kinase regulation. Curr Opin Cell Biology 1995; 7: 773-80.
5. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.
6. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: The role of the p53 tumor-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409-16.
7. Buckley N, Bates AS, Bromme JC, et al. p53 protein accumulates in Cushing adenomas and invasive non-functional adenomas. J Clin Endocrinol Metab 1994; 79: 1513-6.
8. He Y, Li M, Shang X. The relationship between p53 mutation and esophageal cancer biological behavior. Chung-Hua-l-Hsueh-l-Chuan-Hsueg-Tsa-Chi 1998; 15: 1-4.
9. Marchetti A, Buttitta F, Merlo G, et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993; 53: 2846-51.
10. Ainsworth PJ, Surch LC, Coulter-Mackie M. Dignostic single strand conformational polymorphism (SSCP): a simplified non-radioisotopic methos as applied to a Tay-Sachs B1 variant. Nucleic Acids Res 1991; 19: 405-6.
11. Herman F, Drazin NZ, Gonsky R, Melmed S. Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 1993; 77: 50-5.
12. Levy A, Hall S, Yeudall WA, Lightman SL. p53 mutations in pituitary adenoma: rare events. Clin Endocrinol 1994; 41: 809-14.
13. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 1996; 38: 765-71.
14. Battifora H. p53 immunohistochemistry: a word of caution. Hum Pathol 1994; 25: 435-6.
15. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.